A Novel Iron-Based Supplement for Athletes Aged 14-17

NCT06338787 · tracked via the Priya Life Science Canada tracker

Sponsor

University of Calgary

Phase

Not applicable

Started

2024-06-17

Last updated

2025-05-28

Condition(s) studied

Iron Deficiencies

Investigational drug(s) / intervention(s)

FeSC

FeSC: Iron/yeast complex

Study summary

Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study aims to assess the efficacy of a novel iron supplement in improving iron status, gut microbiome, and exercise performance in endurance-trained females.

Eligibility

Sex

FEMALE

Min age

14 Years

Max age

17 Years

Healthy volunteers

Accepted

Inclusion Criteria: * cis-gendered female 14-18 years old * sub-optimal iron status (ferritin ≤45mcg/ L) * At least 1 year past the age of menarche * Engage in moderate to vigorous endurance activity for at least 3 hours a week Exclusion Criteria: * Supplemented with iron iron (\>5mg/day), prebiotics, or probiotics in last 3 months * antibiotic use in last 3 months * \- Energy availability \>30 kcal/kg lean body mass

Primary outcome measure(s)

Iron Status — Baseline, 4 weeks, 8 weeks
Ferritin
Hemoglobin — Baseline, 4 weeks, 8 weeks
Hemoglobin concentration
Lower Gut microbiome — Baseline, 4 weeks, 8 weeks
Fecal sample

Trial sites (1)

Facility	City	Region	Status
University of Calgary	Calgary	Alberta

More University of Calgary trials in Canada

A Novel Iron-Based Supplement for Athletes Aged 18-25: Phase II Active, not recruiting

Spinal Cord Stimulation for Blood Pressure Control in Hypertension Starting soon

CAlgary SAlt for POTS Recruiting

Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section. Recruiting

Transauricular Vagus Nerve Stimulation for Chronic Whiplash Associated Disorders Recruiting

Other trials for the same condition

A Novel Iron-Based Supplement for Athletes Aged 18-25: Phase II Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06338787 on ClinicalTrials.gov ↗ ← All trials in Canada